CSF2 and melanoma: In this sense, a rigorous follow‐up is recommended for early‐stage melanoma patients with a high Breslow thickness, high serum IL‐4 levels, and low GM‐CSF and DCD levels at the time of diagnosis, given the elevated risk for these patients to develop metastasis during follow‐up.